Adlai Nortye Ltd. (ANL)

KY — Healthcare Sector
Peers: GOVX  BLRX  THAR  ADAP  APLM  AIMD  OSRH  LPCN  ADTX  ICU 

Automate Your Wheel Strategy on ANL

With Tiblio's Option Bot, you can configure your own wheel strategy including ANL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ANL
  • Rev/Share 0.0
  • Book/Share 2.3948
  • PB 4.1423
  • Debt/Equity 1.0683
  • CurrentRatio 1.4123
  • ROIC -1.0414

 

  • MktCap 309870385.0
  • FreeCF/Share -4.8853
  • PFCF -5.9603
  • PE -2.0342
  • Debt/Assets 0.382
  • DivYield 0
  • ROE -0.9895

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade ANL H.C. Wainwright Neutral Buy -- $16 Feb. 13, 2026
Downgrade ANL H.C. Wainwright Buy Neutral -- -- June 2, 2025

News

Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year?
ANL
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Positive

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Read More
image for news Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year?
Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
ANL
Published: February 03, 2026 by: GlobeNewsWire
Sentiment: Neutral

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.

Read More
image for news Adlai Nortye Announces $140.0 Million Private Placement Equity Financing

About Adlai Nortye Ltd. (ANL)

  • IPO Date 2023-09-29
  • Website https://www.adlainortye.com
  • Industry Biotechnology
  • CEO Yang Lu
  • Employees 123
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.